Oral Session 3-5C MDS: Basic/Clinical

[OS3-5C-1] Comprehensive analysis for genetic factors predictive of azacitidine treatment for MDS

Yasuhito Nannya¹, June Takeda¹, Shinya Sato², Lanying Zhao¹, Yusuke Shiozawa^1,3, Yuichi Shiraishi⁴, Kenichi Chiba⁴, Hiroko Tanaka⁴, Masashi Sanada⁵, Nobuhiko Nakamura⁶, Hisashi Tsurumi⁶, Yuhei Shibata^6,7, Senji Kasahara⁷, Rena Kamijo⁸, Masataka Taguchi^2,8, Hiroshi Handa⁹, Kensuke Usuki¹⁰, Akifumi Takaori-Kondo¹¹, Shigeru Chiba¹², Norio Asou¹³, Hitoshi Kiyoi¹⁴, Tomoki Naoe⁵, Hideki Makishima¹, Kenichi Yoshida¹, Satoru Miyano⁴, Yasushi Miyazaki², Seishi Ogawa¹ (1.Pathol. and Tumor Biol., Kyoto Univ., Kyoto, Japan, 2.Dep. of Hematol, Nagasaki Univ., Nagasaki, Japan, 3.Dep. of Pediatrics, Tokyo Univ., Tokyo, Japan, 4.Lab of DNA information Analysis,HGC, Univ of Tokyo, Tokyo, Japan., 5.Nagoya Medical Center, Nagoya, Japan, 6.Dep. of Hematol., Gifu University, Gifu, Japan, 7.Dep. of Hematol., Gifu Municipal Hospital, Gifu, Japan, 8.Dep. of Hematol., Sasebo City General Hospital, Nagasaki, Japan, 9.Dep. of Hematol., Gunma University, Gunma, Japan, 10.Dep. of Hematol., NTT Medical Center, Tokyo, Japan, 11.Dep. of Hematol., Kyoto University, Kyoto, Japan, 12.Dep. of Hematol., Univ. of Tsukuba, Ibaraki, Japan, 13.Dep. of Hematol, Saitama Medical Univ IMC, Hidaka, Japan, 14.Dep. of Hematol, Nagoya Univ, Nagoya, Japan, 15.Dep. of Hematol, Kanazawa Univ, Kanazawa, Japan, 16.Dep. of Hematol, Tokyo Medical University, Tokyo, Japan)